Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco

BACKGROUND: The Kingdom of Morocco approved BBIBP-CorV (Sinopharm) COVID-19 vaccine for emergency use on 22 January 2021 in a two-dose, three-to-four-week interval schedule. We conducted a retrospective cohort study to determine real-world BBIBP-CorV vaccine effectiveness (VE) against serious or cri...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yaowen, Belayachi, Jihane, Yang, Yunkai, Fu, Qiang, Rodewald, Lance, Li, Hongling, Yan, Bing, Wang, Ying, Shen, Yanna, Yang, Qian, Mu, Weiyun, Tang, Rong, Su, Chen, Xu, Tianfang, Obtel, Majdouline, Mhayi, Abdelkader, Razine, Rachid, Abouqal, Redouane, Zhang, Yuntao, Yang, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392069/
https://www.ncbi.nlm.nih.gov/pubmed/35987605
http://dx.doi.org/10.1186/s12889-022-14016-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392069/
https://www.ncbi.nlm.nih.gov/pubmed/35987605
http://dx.doi.org/10.1186/s12889-022-14016-9

Ejemplares similares